DecImmune partners with DSM to develop antibody drugs

04/24/2013 | Pharmaceutical Business Review Online

DSM Pharmaceutical Products agreed to develop DecImmune Therapeutics' monoclonal antibody program. DecImmune is working on an antibody-based drug to block activation of the N2 neoepitope and protect tissues and organs. Beginning development activities will be carried out at DSM Biologics' plant in Groningen, Netherlands.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC